215 related articles for article (PubMed ID: 32594372)
1. Bardoxolone methyl: drug development for diabetic kidney disease.
Kanda H; Yamawaki K
Clin Exp Nephrol; 2020 Oct; 24(10):857-864. PubMed ID: 32594372
[TBL] [Abstract][Full Text] [Related]
2. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.
de Zeeuw D; Akizawa T; Audhya P; Bakris GL; Chin M; Christ-Schmidt H; Goldsberry A; Houser M; Krauth M; Lambers Heerspink HJ; McMurray JJ; Meyer CJ; Parving HH; Remuzzi G; Toto RD; Vaziri ND; Wanner C; Wittes J; Wrolstad D; Chertow GM;
N Engl J Med; 2013 Dec; 369(26):2492-503. PubMed ID: 24206459
[TBL] [Abstract][Full Text] [Related]
3. Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease.
Rossing P; Block GA; Chin MP; Goldsberry A; Heerspink HJL; McCullough PA; Meyer CJ; Packham D; Pergola PE; Spinowitz B; Sprague SM; Warnock DG; Chertow GM
Kidney Int; 2019 Oct; 96(4):1030-1036. PubMed ID: 31377056
[TBL] [Abstract][Full Text] [Related]
4. Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: design and baseline characteristics of the AYAME study.
Nangaku M; Takama H; Ichikawa T; Mukai K; Kojima M; Suzuki Y; Watada H; Wada T; Ueki K; Narita I; Kashihara N; Kadowaki T; Hase H; Akizawa T
Nephrol Dial Transplant; 2023 May; 38(5):1204-1216. PubMed ID: 36002026
[TBL] [Abstract][Full Text] [Related]
5. Oxidative Stress and NRF2/KEAP1/ARE Pathway in Diabetic Kidney Disease (DKD): New Perspectives.
Tanase DM; Gosav EM; Anton MI; Floria M; Seritean Isac PN; Hurjui LL; Tarniceriu CC; Costea CF; Ciocoiu M; Rezus C
Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139066
[TBL] [Abstract][Full Text] [Related]
6. Randomized Clinical Trial on the Effect of Bardoxolone Methyl on GFR in Diabetic Kidney Disease Patients (TSUBAKI Study).
Nangaku M; Kanda H; Takama H; Ichikawa T; Hase H; Akizawa T
Kidney Int Rep; 2020 Jun; 5(6):879-890. PubMed ID: 32518870
[TBL] [Abstract][Full Text] [Related]
7. Effects of NRF2 polymorphisms on safety and efficacy of bardoxolone methyl: subanalysis of TSUBAKI study.
Ikejiri K; Suzuki T; Muto S; Takama H; Yamawaki K; Miyazawa T; Urakawa I; Aoki Y; Otsuki A; Katsuoka F; Kinoshita K; Nangaku M; Akizawa T; Yamamoto M
Clin Exp Nephrol; 2024 Mar; 28(3):225-234. PubMed ID: 37962746
[TBL] [Abstract][Full Text] [Related]
8. Diabetic nephropathy: Could problems with bardoxolone methyl have been predicted?
Rossing P
Nat Rev Nephrol; 2013 Mar; 9(3):128-30. PubMed ID: 23381371
[No Abstract] [Full Text] [Related]
9. [Challenges in kidney disease: therapeutic potential of bardoxolone methyl].
Yamawaki K
Nihon Yakurigaku Zasshi; 2022; 157(4):261-264. PubMed ID: 35781457
[TBL] [Abstract][Full Text] [Related]
10. Keap1-Nrf2 signaling activation by Bardoxolone-methyl ameliorates high glucose-induced oxidative injury in human umbilical vein endothelial cells.
Yang JL; Sun MY; Yuan Q; Tang S; Dong MJ; Zhang RD; Liu YY; Mao L
Aging (Albany NY); 2020 Jun; 12(11):10370-10380. PubMed ID: 32484788
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl.
Chin MP; Wrolstad D; Bakris GL; Chertow GM; de Zeeuw D; Goldsberry A; Linde PG; McCullough PA; McMurray JJ; Wittes J; Meyer CJ
J Card Fail; 2014 Dec; 20(12):953-8. PubMed ID: 25307295
[TBL] [Abstract][Full Text] [Related]
12. Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study.
Chin MP; Bakris GL; Block GA; Chertow GM; Goldsberry A; Inker LA; Heerspink HJL; O'Grady M; Pergola PE; Wanner C; Warnock DG; Meyer CJ
Am J Nephrol; 2018; 47(1):40-47. PubMed ID: 29402767
[TBL] [Abstract][Full Text] [Related]
13. Diabetes: bardoxolone improves kidney function in type 2 diabetes.
Thomas MC; Cooper ME
Nat Rev Nephrol; 2011 Aug; 7(10):552-3. PubMed ID: 21862993
[No Abstract] [Full Text] [Related]
14. Targeting the KEAP1-NRF2 System to Prevent Kidney Disease Progression.
Nezu M; Suzuki N; Yamamoto M
Am J Nephrol; 2017; 45(6):473-483. PubMed ID: 28502971
[TBL] [Abstract][Full Text] [Related]
15. Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease.
Chertow GM; Appel GB; Block GA; Chin MP; Coyne DW; Goldsberry A; Kalantar-Zadeh K; Meyer CJ; Molitch ME; Pergola PE; Raskin P; Silva AL; Spinowitz B; Sprague SM; Rossing P
J Diabetes Complications; 2018 Dec; 32(12):1113-1117. PubMed ID: 30318163
[TBL] [Abstract][Full Text] [Related]
16. Novel Keap1-Nrf2 Protein-Protein Interaction Inhibitor UBE-1099 Ameliorates Progressive Phenotype in Alport Syndrome Mouse Model.
Kaseda S; Sannomiya Y; Horizono J; Kuwazuru J; Suico MA; Ogi S; Sasaki R; Sunamoto H; Fukiya H; Nishiyama H; Kamura M; Niinou S; Koyama Y; Nara F; Shuto T; Onuma K; Kai H
Kidney360; 2022 Apr; 3(4):687-699. PubMed ID: 35721612
[TBL] [Abstract][Full Text] [Related]
17. Bardoxolone methyl decreases megalin and activates nrf2 in the kidney.
Reisman SA; Chertow GM; Hebbar S; Vaziri ND; Ward KW; Meyer CJ
J Am Soc Nephrol; 2012 Oct; 23(10):1663-73. PubMed ID: 22859857
[TBL] [Abstract][Full Text] [Related]
18. Bardoxolone-the Phoenix?
Toto RD
J Am Soc Nephrol; 2018 Feb; 29(2):360-361. PubMed ID: 29371416
[No Abstract] [Full Text] [Related]
19. A preliminary evaluation of bardoxolone methyl for the treatment of diabetic nephropathy.
Thomas M
Expert Opin Drug Metab Toxicol; 2012 Aug; 8(8):1015-22. PubMed ID: 22747345
[TBL] [Abstract][Full Text] [Related]
20. [Bardoxolone: a new potential therapeutic agent in the treatment of autosomal dominant polycystic kidney disease?].
Celentano S; Capolongo G; Pollastro RM
G Ital Nefrol; 2019 Sep; 36(5):. PubMed ID: 31580543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
